Literature DB >> 20471429

Potent inhibition of influenza virus replication with novel siRNA-chimeric-ribozyme constructs.

Prashant Kumar1, Vikas Sood, Rajesh Vyas, Nidhi Gupta, Akhil C Banerjea, Madhu Khanna.   

Abstract

A multitarget approach is needed for effective gene silencing for RNA viruses that combines, more than one antiviral approach. Towards this end, we designed a wild-type (wt) chimeric construct, that consisted of small hairpin siRNA joined by a short intracellular cleavable linker to a known, hammerhead ribozyme (Rz), both targeted against M1 genome segment of influenza A virus. When this, wt chimeric RNA construct was introduced into a mammalian cell line, along with the M1 substrate, encoding DNA, very significant (67%) intracellular down regulation in the levels of target RNA was, observed. When the siRNA portion of this chimeric construct was mutated keeping the Rz region, unchanged, it caused only 33% intracellular reduction. On the contrary, when only the Rz was made, catalytically inactive, keeping the siRNA component unchanged, about 20% reduction in the target M1, specific RNA was observed. This wt chimeric construct showed impressive (>80%) protection against, virus challenge, on the other hand, the selectively disabled mutant constructs were less effective. Thus, in this proof of concept study we show that varying levels of protection against virus challenge was, observed with novel mutant versions of the chimeric constructs. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471429     DOI: 10.1016/j.antiviral.2010.05.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

1.  Nucleic acid-mediated cleavage of M1 gene of influenza A virus is significantly augmented by antisense molecules targeted to hybridize close to the cleavage site.

Authors:  B Kumar; Madhu Khanna; P Kumar; V Sood; R Vyas; A C Banerjea
Journal:  Mol Biotechnol       Date:  2012-05       Impact factor: 2.695

2.  Disruption of dengue virus transmission by mosquitoes.

Authors:  Alexander W E Franz; Velmurugan Balaraman; Malcolm J Fraser
Journal:  Curr Opin Insect Sci       Date:  2015-04-01       Impact factor: 5.186

3.  Potent Intracellular Knock-Down of Influenza A Virus M2 Gene Transcript by DNAzymes Considerably Reduces Viral Replication in Host Cells.

Authors:  Binod Kumar; Roopali Rajput; Dibya Ranjan Pati; Madhu Khanna
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

4.  Structural variants and modifications of hammerhead ribozymes targeting influenza A virus conserved structural motifs.

Authors:  Tomasz Czapik; Julita Piasecka; Ryszard Kierzek; Elzbieta Kierzek
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-31       Impact factor: 10.183

5.  Cross-protective effect of antisense oligonucleotide developed against the common 3' NCR of influenza A virus genome.

Authors:  Prashant Kumar; Binod Kumar; Roopali Rajput; Latika Saxena; Akhil C Banerjea; Madhu Khanna
Journal:  Mol Biotechnol       Date:  2013-11       Impact factor: 2.695

6.  Resolution of immune response by recombinant transforming growth factor-beta (rTGF-β) during influenza A virus infection.

Authors:  Vikram Srivastava; Madhu Khanna; Sonal Sharma; Binod Kumar
Journal:  Indian J Med Res       Date:  2012-10       Impact factor: 2.375

7.  A novel ribozyme-based prophylaxis inhibits influenza A virus replication and protects from severe disease.

Authors:  Julie Motard; Ronan Rouxel; Alexandra Paun; Veronika von Messling; Martin Bisaillon; Jean-Pierre Perreault
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

Review 8.  Therapeutics against influenza.

Authors:  Elena A Govorkova; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 9.  RNA Secondary Structure as a First Step for Rational Design of the Oligonucleotides towards Inhibition of Influenza A Virus Replication.

Authors:  Marta Szabat; Dagny Lorent; Tomasz Czapik; Maria Tomaszewska; Elzbieta Kierzek; Ryszard Kierzek
Journal:  Pathogens       Date:  2020-11-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.